Singapore markets closed

The Greater Cannabis Company, Inc. (GCAN)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0006-0.0001 (-14.29%)
At close: 02:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.0007
Open0.0011
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0006 - 0.0008
52-week range0.0003 - 0.0015
Volume10,424,967
Avg. volume4,095,138
Market cap482,782
Beta (5Y monthly)1.56
PE ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

    BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy. The Company had previously announced the preclinical study as part of its license and research agreement with Shaare Zedek Scientific related